Late-breaking poster presentation to showcase initial activity of WAL0921 in proteinuric kidney disease Additional poster demonstrates WAL0921 is safe, well tolerated, and reduces ...
Fate Therapeutics, Inc. (NASDAQ: FATE), a clinical-stage biopharmaceutical company dedicated to bringing a transformative pipeline of induced pluripotent stem cell (iPSC)-derived cellular ...
Medical Aesthetics data and intelligence provider Guidepoint Qsight today released a new report, The Brotox Boom: U.S. Male Neurotoxin Spend Hits Record High, showing that American men are spending ...
Abeona Therapeutics Inc. (Nasdaq: ABEO) today announced it has granted equity awards to new non-executive employees who joined the Company. The equity awards were approved in accordance with Nasdaq ...
(“Biosplice”), a late-stage biopharmaceutical company developing lorecivivint (“LOR”), a first-in-class small-molecule inhibitor of CLK/DYRK kinases, for the treatment of knee osteoarthritis (“OA”), ...
Pyxis Oncology, Inc. (Nasdaq: PYXS or the “Company”), a clinical-stage company developing next-generation therapeutics for difficult-to-treat cancers, today announced that it closed its previously ...
InflaRx N.V. (Nasdaq: IFRX), a biopharmaceutical company pioneering anti-inflammatory therapeutics by targeting the complement system, today announced that the Company has been selected for a ...
Employers can now deliver GLP-1 and hormone replacement therapy through a unified care team, without layering on another standalone point solution MOUNTAIN VIEW, Calif., Oct. 02, 2026 (GLOBE NEWSWIRE) ...
Cytokinetics, Incorporated (Nasdaq: CYTK) today announced four upcoming presentations, including two Late Breaking Clinical Research presentations and two oral presentations, at the Heart Failure ...
The Ensign Group, Inc. (Nasdaq: ENSG), the parent company of the Ensign™ group of companies, which invest in and provide skilled nursing and senior living services, physical, occupational and speech ...
Kura Oncology, Inc. (the “Company”) (Nasdaq: KURA), a biopharmaceutical company focused on precision medicines for the treatment of cancer, today announced that on October 1, 2026, the Compensation ...
The Ensign Group, Inc. (Nasdaq: ENSG), the parent company of the Ensign TM group of companies, which invest in and p ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results